Assertion: harpoon | /r/CapableOf | announce in april
Facets:
Source sentences:
text: In April, Harpoon announced the first patient was dosed with HPN217 in a Phase 1/2 clinical trial focused on relapsed/refractory multiple myeloma (RRMM).